Evaluation of Homocysteine and Gamma-Glutamyl Transferase Concentrations As Markers of Chronic Kidney Disease: An Indian Perspective.
chronic kidney disease
end-stage renal disease
gamma-glutamyl transferase
glomerular filtration rate
homocysteine
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
08
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Background Chronic kidney disease (CKD) involves a gradual loss of kidney function over months to years. Oxidative stress plays a critical role in the pathogenesis of CKD. Homocysteine (Hcy), an amino acid derivative, is a known risk factor for oxidative stress and endothelial damage. Gamma-glutamyl transferase (GGT), an enzyme abundant on the cell surface of liver and kidney cells, is raised during oxidative stress. The objectives of this study were to estimate the concentrations of serum Hcy and GGT among CKD patients and healthy controls and to determine whether there is an association between serum Hcy and GGT levels in CKD. Methodology A total of 246 participants were needed to meet the calculated sample size. A total of 123 CKD patients meeting the inclusion and exclusion criteria were recruited as cases from the Nephrology outpatient department of our institute. Equal numbers of age- and sex-matched healthy volunteers were recruited as controls. Biophysical profiling of participants was done. Baseline investigations were recorded. A blood sample was collected from each participant and analyzed for GGT and Hcy along with other routine parameters. Results Hcy and GGT concentrations were significantly high in CKD patients compared to healthy controls. There was a significant positive correlation between serum GGT and Hcy levels (r = 0.357). Conclusions Elevated levels of GGT and Hcy in CKD patients compared to healthy controls demonstrated the oxidative stress associated with the disease. GGT and Hcy can be used as prognostic markers of the disease.
Identifiants
pubmed: 35411265
doi: 10.7759/cureus.22959
pmc: PMC8989248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e22959Informations de copyright
Copyright © 2022, R et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Nephrol. 2007;27(3):262-8
pubmed: 17396029
Dis Markers. 2017;2017:9765259
pubmed: 28659657
Methods Enzymol. 2005;401:468-83
pubmed: 16399403
Pediatr Nephrol. 2019 Jun;34(6):975-991
pubmed: 30105414
Fam Pract. 2018 May 23;35(3):259-265
pubmed: 29092063
Int Urol Nephrol. 2017 Feb;49(2):303-312
pubmed: 27704320
J Diabetes Res. 2019 Feb 17;2019:7825804
pubmed: 30911552
Circ Res. 2016 Nov 11;119(11):1226-1241
pubmed: 27992360
Clin Chim Acta. 2011 Jul 15;412(15-16):1407-11
pubmed: 21527256
Int J Geriatr Psychiatry. 2016 Jul;31(7):723-30
pubmed: 26553116
Adv Clin Chem. 2015;72:77-106
pubmed: 26471081
Oxid Med Cell Longev. 2020 Jan 23;2020:5478708
pubmed: 32082479
Int J Appl Basic Med Res. 2015 Jan-Apr;5(1):31-5
pubmed: 25664265
PLoS One. 2014 Dec 11;9(12):e114970
pubmed: 25500578
Clin Chim Acta. 2017 Oct;473:39-44
pubmed: 28811239
Nefrologia. 2017 May - Jun;37(3):267-275
pubmed: 28648203
Cochrane Database Syst Rev. 2016 May 31;(5):CD004683
pubmed: 27243372
Kidney Blood Press Res. 2010;33(1):1-6
pubmed: 20090360
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Clin Chem. 2007 Jan;53(1):71-7
pubmed: 17110470
Am J Nephrol. 2010;31(5):442-55
pubmed: 20395677